Foghorn Therapeutics, a company advancing a class of therapeutics targeting the chromatin regulatory system in oncology, has entered into a collaboration with Merck, known as MSD outside the U.S. and Canada. The collaboration will apply Foghorn’s proprietary Gene Traffic Control product platform to discover and develop novel therapeutics against a transcription factor target believed to be relevant to a broad range of cancer patients.   The target is one of Foghorn’s growing number of programs e...